Your Yourlocation: Home > The addition of once-daily tiotropium bromide(136310-93-5) to severe asthma treatment significantly improves lung functions

Background and Objectives: In substantial proportion of patients severe asthma has been a poorly controlled disease, with recurring symptoms and exacerbations despite the use of inhaled glucocorticoids (ICS), long-acting beta-agonists (LABAs-2), leukotriene receptor antagonist (LTRA), and theophyllines. Addition of a second bronchodilator with an alternative mode of action is a potential alternative approach, the anticholinergic tiotropium bromide(136310-93-5). Therefore, the aim of this study was to assess the clinical efficacy of tiotropium 18 mcg as an adjunct to severe asthma.

Methodology: Single-blinded randomized trials were carried in patients with severe asthma. Patients were randomized into two groups. The study group received 18mcg of tiotropium bromide(136310-93-5), while the two groups continued on the combination of LABA and high-dose ICS, theophylline and LTRA. Improvement in lung function (forced expiratory volume in 1 s [FEV1], forced vital capacity [FVC], and peak expiratory flow rate [PEFR]), clinical symptoms, and quality of life were assessed by mini asthma quality of life questionnaire (mini-AQLQ) at 4, 8, and 12 weeks.

Results: Seventy patients were included in the study, 63 of whom completed the study period. Baseline features were well matched between the groups. At the end of 12 weeks, the tiotropium bromide(136310-93-5) group showed a mean improvement in FEV1 and FVC of 450 ml and 560 ml, respectively, as compared to the control group (P < 0.0001). PEFR showed mean difference of 16.8 L/min in the study group at the end of 12 weeks as compared to the control group and it was statistically significant (P < 0.0001). The quality of life assessed by mini-AQLQ was statistically significant in the study group (3.42 versus 3.07; P <0.0001) compared to the control group. In the study group, approximately 21 patients (65.62%) did not exacerbate compared with 8 patients (25.8%) in the control group (P = 0.045).

Conclusions: The use of tiotropium bromide(136310-93-5) once a day significantly improved lung function and quality of life for 12-week treatment in severe asthma treatment regimens, including high-dose ICS plus LABA, theophylline and LTRA.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved